HK1216174A1 - 氨基取代的咪唑並 吡啶羧酰胺和它們的用途 - Google Patents

氨基取代的咪唑並 吡啶羧酰胺和它們的用途

Info

Publication number
HK1216174A1
HK1216174A1 HK16104153.7A HK16104153A HK1216174A1 HK 1216174 A1 HK1216174 A1 HK 1216174A1 HK 16104153 A HK16104153 A HK 16104153A HK 1216174 A1 HK1216174 A1 HK 1216174A1
Authority
HK
Hong Kong
Prior art keywords
pyridinecarboxamides
amino
substituted imidazo
imidazo
substituted
Prior art date
Application number
HK16104153.7A
Other languages
English (en)
Inventor
Alexandros Vakalopoulos
Markus Follmann
Ingo Hartung
Philipp Buchgraber
Rolf Jautelat
Jorma Ha�Feld
Niels Lindner
Alexey Gromov
Frank Wunder
Johannes-Peter Stasch
Gorden Redlich
Volkhart Min-Jian Li
Eva Maria Becker-Pelster
Andreas Knorr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/789,655 external-priority patent/US9126998B2/en
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1216174A1 publication Critical patent/HK1216174A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16104153.7A 2012-11-05 2016-04-12 氨基取代的咪唑並 吡啶羧酰胺和它們的用途 HK1216174A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12191201 2012-11-05
US13/789,655 US9126998B2 (en) 2012-11-05 2013-03-07 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
EP13178248 2013-07-26
PCT/EP2013/072891 WO2014068099A1 (de) 2012-11-05 2013-11-04 Amino-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung

Publications (1)

Publication Number Publication Date
HK1216174A1 true HK1216174A1 (zh) 2016-10-21

Family

ID=50626532

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104153.7A HK1216174A1 (zh) 2012-11-05 2016-04-12 氨基取代的咪唑並 吡啶羧酰胺和它們的用途

Country Status (42)

Country Link
US (4) US9624214B2 (zh)
EP (2) EP2914594B1 (zh)
JP (1) JP6423796B2 (zh)
KR (1) KR102122779B1 (zh)
CN (1) CN104981470B (zh)
AP (1) AP2015008411A0 (zh)
AR (1) AR093364A1 (zh)
AU (1) AU2013340726B2 (zh)
BR (1) BR112015010072B1 (zh)
CA (1) CA2890356C (zh)
CL (1) CL2015001163A1 (zh)
CR (1) CR20150232A (zh)
DK (1) DK2914594T3 (zh)
DO (1) DOP2015000099A (zh)
EA (1) EA033626B1 (zh)
EC (1) ECSP15017505A (zh)
ES (1) ES2635412T3 (zh)
GT (1) GT201500105A (zh)
HK (1) HK1216174A1 (zh)
HR (1) HRP20171179T1 (zh)
HU (1) HUE035408T2 (zh)
IL (1) IL238493B (zh)
JO (1) JO3397B1 (zh)
LT (1) LT2914594T (zh)
ME (1) ME02811B (zh)
MX (1) MX363984B (zh)
MY (1) MY192724A (zh)
NZ (1) NZ706728A (zh)
PE (1) PE20150883A1 (zh)
PH (1) PH12015500988B1 (zh)
PL (1) PL2914594T3 (zh)
PT (1) PT2914594T (zh)
RS (1) RS56314B1 (zh)
SG (2) SG11201502729XA (zh)
SI (1) SI2914594T1 (zh)
SV (1) SV2015004969A (zh)
TN (1) TN2015000169A1 (zh)
TW (1) TWI630206B (zh)
UA (1) UA115887C2 (zh)
UY (1) UY35115A (zh)
WO (1) WO2014068099A1 (zh)
ZA (1) ZA201503828B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778964B2 (en) * 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
JP2017508810A (ja) * 2014-03-21 2017-03-30 バイエル・ファルマ・アクティエンゲゼルシャフト シアノ置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
CN106470995A (zh) * 2014-05-02 2017-03-01 拜耳医药股份有限公司 用于治疗心血管疾病的作为可溶性鸟苷酸环化酶刺激物的咪唑并[1,2‑a]吡啶类
EP3137465A1 (de) * 2014-05-02 2017-03-08 Bayer Pharma Aktiengesellschaft 6-chlor-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung als stimulatoren der löslichen guanylatcyclase
JP2017536396A (ja) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロアリール置換イミダゾ［１，２−ａ］ピリジンおよびその使用
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
EP3286185A1 (de) * 2015-02-05 2018-02-28 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung
CA2975668A1 (en) * 2015-02-05 2016-08-11 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrazine carboxamides and use thereof
JP6748113B2 (ja) 2015-05-06 2020-08-26 バイエル・ファルマ・アクティエンゲゼルシャフト 全身性硬化症（ＳＳｃ）に付随する指潰瘍（ＤＵ）を治療するための単独のまたはＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤、ｓＧＣ活性化剤の使用
AU2016275764B8 (en) 2015-06-11 2021-03-04 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
SI3325013T2 (sl) 2015-07-23 2023-11-30 Bayer Pharma Aktiengesellschaft Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
JOP20170113B1 (ar) * 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
PT3507291T (pt) 2016-09-02 2021-08-30 Cyclerion Therapeutics Inc Estimulantes de sgc bicíclicos fundidos
JP7101688B2 (ja) 2016-10-11 2022-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
MA50440A (fr) 2017-10-24 2020-09-02 Bayer Ag Imidazopyridinamides substituées et leur utilisation
WO2019211081A1 (en) * 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EP3566704A1 (en) 2018-05-11 2019-11-13 Bayer Aktiengesellschaft The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases
WO2019219672A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
MA53127A (fr) 2018-07-11 2021-05-19 Cyclerion Therapeutics Inc Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
WO2023126437A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft Treatment of cardiopulmonary disorders
AR128147A1 (es) 2021-12-29 2024-03-27 Bayer Ag Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4’-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo
TW202342035A (zh) 2021-12-29 2023-11-01 德商拜耳廠股份有限公司 醫藥乾粉吸入配製物
WO2024102699A1 (en) * 2022-11-07 2024-05-16 ELANCO US, Inc. Guanylate cyclase (gc) stimulator formulations and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0266890A1 (en) * 1986-10-07 1988-05-11 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them
SE8704248D0 (sv) 1987-10-30 1987-10-30 Haessle Ab Medical use
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
US5593993A (en) 1991-08-02 1997-01-14 Medivir Ab Method for inhibition of HIV related viruses
FR2714907B1 (fr) 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
CA2196263C (en) 1996-02-09 2004-10-26 Barry Jackson Process for the preparation of 4-oxoimidazolinium salts
EP0802192A1 (de) 1996-04-17 1997-10-22 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DK1277754T3 (da) 2000-04-27 2005-11-14 Astellas Pharma Inc Imidazopyridinderivater
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
AU2003278729A1 (en) 2002-09-01 2004-03-19 Washington University Regulated bacterial lysis for gene vaccine vector delivery and antigen release
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2006015737A1 (de) 2004-08-02 2006-02-16 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
DK1902026T3 (da) 2005-06-24 2010-04-26 Lilly Co Eli Tetrahydrocarbazol-derivater, der kan anvendes som androgen-receptor-modulatorer (SARM)
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
RU2439062C2 (ru) 2006-10-19 2012-01-10 Ф.Хоффманн-Ля Рош Аг Производные имидазолона и имидазолидинона как 11в-hsd1 ингибиторы при диабете
DE102006054562A1 (de) 2006-11-20 2008-05-21 Bayer Healthcare Ag Verfahren zum Nachweis von Pyrophosphat mit Biolumineszenz Detektion
EP2134713A2 (en) 2006-12-20 2009-12-23 Schering Corporation Novel jnk inhibitors
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG184073A1 (en) 2010-03-18 2012-10-30 Pasteur Institut Korea Anti-infective compounds
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
JP5409961B2 (ja) 2010-05-27 2014-02-05 メルク・シャープ・エンド・ドーム・コーポレイション 可溶性グアニル酸シクラーゼアクチベーター
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
KR20140040774A (ko) 2011-05-30 2014-04-03 아스테라스 세이야쿠 가부시키가이샤 이미다조피리딘 화합물
US9126998B2 (en) * 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) * 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) * 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
JP6056872B2 (ja) 2012-11-30 2017-01-11 アステラス製薬株式会社 イミダゾピリジン化合物
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
JP2016529249A (ja) 2013-08-08 2016-09-23 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］ピリジン−３−カルボキサミドおよびその使用
CN105899510A (zh) 2013-08-08 2016-08-24 拜耳制药股份公司 取代的咪唑并[1,2-a]吡嗪羧酰胺及其用途
CA2932482A1 (en) 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- and hetaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides and use thereof
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
JP2017508810A (ja) 2014-03-21 2017-03-30 バイエル・ファルマ・アクティエンゲゼルシャフト シアノ置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
CN106103438A (zh) 2014-03-21 2016-11-09 拜耳医药股份有限公司 取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
EP3137464A1 (de) 2014-05-02 2017-03-08 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen
CN106470995A (zh) 2014-05-02 2017-03-01 拜耳医药股份有限公司 用于治疗心血管疾病的作为可溶性鸟苷酸环化酶刺激物的咪唑并[1,2‑a]吡啶类

Also Published As

Publication number Publication date
KR20150081336A (ko) 2015-07-13
SI2914594T1 (sl) 2017-08-31
US10052312B2 (en) 2018-08-21
PE20150883A1 (es) 2015-05-27
CA2890356A1 (en) 2014-05-08
CR20150232A (es) 2015-05-29
CA2890356C (en) 2021-04-06
PL2914594T3 (pl) 2017-10-31
JP2016500705A (ja) 2016-01-14
MX2015005610A (es) 2015-09-04
IL238493A0 (en) 2015-06-30
TWI630206B (zh) 2018-07-21
DOP2015000099A (es) 2015-05-31
GT201500105A (es) 2018-12-19
WO2014068099A1 (de) 2014-05-08
SG10201703724UA (en) 2017-06-29
EP3272749A1 (de) 2018-01-24
SV2015004969A (es) 2017-06-07
AP2015008411A0 (en) 2015-05-31
SG11201502729XA (en) 2015-05-28
JP6423796B2 (ja) 2018-11-14
ME02811B (me) 2018-01-20
EP2914594A1 (de) 2015-09-09
MY192724A (en) 2022-09-05
MX363984B (es) 2019-04-10
CN104981470B (zh) 2017-04-19
UA115887C2 (uk) 2018-01-10
TW201429966A (zh) 2014-08-01
ECSP15017505A (es) 2016-01-29
TN2015000169A1 (en) 2016-10-03
US20180319794A1 (en) 2018-11-08
AR093364A1 (es) 2015-06-03
DK2914594T3 (en) 2017-08-28
US20150274719A1 (en) 2015-10-01
EA201590870A1 (ru) 2015-11-30
PT2914594T (pt) 2017-08-02
US20140179672A1 (en) 2014-06-26
US20190248783A9 (en) 2019-08-15
NZ706728A (en) 2019-02-22
PH12015500988A1 (en) 2015-07-13
UY35115A (es) 2014-05-30
BR112015010072B1 (pt) 2021-11-30
HUE035408T2 (en) 2018-05-02
JO3397B1 (ar) 2019-10-20
EA033626B1 (ru) 2019-11-11
AU2013340726A1 (en) 2015-05-21
US9624214B2 (en) 2017-04-18
LT2914594T (lt) 2017-08-10
PH12015500988B1 (en) 2015-07-13
EP2914594B1 (de) 2017-05-03
ES2635412T3 (es) 2017-10-03
RS56314B1 (sr) 2017-12-29
US10662185B2 (en) 2020-05-26
KR102122779B1 (ko) 2020-06-26
ZA201503828B (en) 2016-09-28
CL2015001163A1 (es) 2015-08-28
CN104981470A (zh) 2015-10-14
US20170182014A1 (en) 2017-06-29
HRP20171179T1 (hr) 2017-10-06
AU2013340726B2 (en) 2018-01-04
IL238493B (en) 2019-03-31
BR112015010072A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
HK1216174A1 (zh) 氨基取代的咪唑並 吡啶羧酰胺和它們的用途
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
HK1221469A1 (zh) -芳基-取代的咪唑並 吡啶及其用途
HK1215437A1 (zh) 羧基取代的咪唑並 吡啶甲醯胺及其作爲可溶性鳥苷酸環化酶的刺激物的用途
HK1212335A1 (zh) 羥基取代的咪唑並 吡啶甲酰胺及其作爲可溶性鳥苷酸環化酶刺激劑的用途
PL2600719T3 (pl) 2-Podstawione 8-alkilo-7-okso-7,8-dihydropirydo[2,3-d]pirymidyno-6-karbonitryle oraz ich zastosowania
IL243525A0 (en) Benzyl-1h-pyrazolo[4,3-b]pyridines and their use
HK1225723A1 (zh) 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
HK1220201A1 (zh) 作爲成像工具的咪唑並 吡啶- -胺類
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
HK1221457A1 (zh) 種吡嗪並 吲哚化合物及其製備方法和在藥物中的應用
HK1205504A1 (zh) 取代的吡唑並 吡啶、其製備及作為藥物的應用
HK1206355A1 (zh) 哌嗪並 吲哚- -酮和 二氮雜䓬並 吲哚- -酮
HK1221458A1 (zh) 種吡嗪並 吲哚化合物及其製備方法和在藥物中的應用
HK1213553A1 (zh) 呱嗪並 吲哚- -酮和 二氮雜*並 吲哚- -酮

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231104